Synthesized peptide derived from human Her-2 AA range: 300-400

The antibody can specifically recognize human Her-2 protein.

ERBB2 HER2 MLN19 NEU NGL

Her-2

Receptor tyrosine-protein kinase erbB-2 ;
Metastatic lymph node gene 19 protein ;
MLN 19 ;
Proto-oncogene Neu ;
Proto-oncogene c-ErbB-2 ;
Tyrosine kinase-type cell surface receptor HER2 ;
p185erbB2 ;
CD antigen CD340 ;

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However , it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer , stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways , such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported , with the most common allele , Ile654/Ile655 , shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers , including breast and ovarian tumors. Alternative splicing results in several additional transcript variants , some encoding d

Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. ,Disease:Defects in ERBB2 are associated with familial glioma of brain [MIM:137800]; also called glioblastoma multiforme. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas , glioblastoma multiforme , oligodendrogliomas , and ependymomas. ,Disease:Defects in ERBB2 are associated with gastric cancer [MIM:137215]; also known as hereditary familial diffuse gastric cancer (HDGC) . ,Disease:Defects in ERBB2 are associated with lung cancer [MIM:211980]; also called adenocarcinoma of lung. ,Disease:Defects in ERBB2 are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of visceral metastases. These typical features relate to the biology of the disease , which is a principal determinant of outcome. ,Function:Essential component of a neuregulin-receptor complex , although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF , TGF-alpha and amphiregulin. ,online information:ERBB2 entry ,polymorphism:There are fours alleles due to the variations in positions 654 and 655. Allele B1 (Ile-654/Ile-655) has a frequency of 0.782; allele B2 (Ile-654/Val-655) has a frequency of 0.206; allele B3 (Val-654/Val-655) has a frequency of 0.012. ,PTM:Ligand-binding increases phosphorylation on tyrosine residues. ,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. ,similarity:Contains 1 protein kinase domain. ,subunit:Heterodimer with each of the other ERBB receptors (Potential) . Interacts with PRKCABP and PLXNB1. Part of a complex with EGFR and either PIK3C2A or PIK3C2B. May interact with PIK3C2B when phosphorylated on Tyr-1196. Interacts with MEMO when phosphorylated on Tyr-1248. Interacts with MUC1. Stimulation by heregulin (HRG) in breast cancer cell lines induces binding of MUC1 with gamma-catenin. ,

[Isoform 1]: Cell membrane ; Single-pass type I membrane protein. Early endosome . Cytoplasm , perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis , probably endosomal sorting and is mediated by importin beta-1/KPNB1. Also detected in VPS35-positive endosome-to-TGN retrograde vesicles (PubMed:31138794) . .; [Isoform 2]: Cytoplasm. Nucleus.; [Isoform 3]: Cytoplasm. Nucleus.

>>EGFR tyrosine kinase inhibitor resistance ;
>>Endocrine resistance ;
>>Platinum drug resistance ;
>>MAPK signaling pathway ;
>>ErbB signaling pathway ;
>>Calcium signaling pathway ;
>>HIF-1 signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Focal adhesion ;
>>Adherens junction ;
>>Tight junction ;
>>Pathways in cancer ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Prostate cancer ;
>>Bladder cancer ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Gastric cancer ;
>>Central carbon metabolism in cancer